J&J Medical Connect
icotrokinra
J&J Medical Connect

Connect with us

Connect with us

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

icotrokinra

Medical Information

Icotrokinra – Dosage and Administration in Phase 3 Plaque Psoriasis Trials

Last Updated: 01/14/2026

SUMMARY  

  • Icotrokinra (JNJ-77242113) is a targeted oral peptide that selectively binds the interleukin-23 (IL-23) receptor and inhibits IL-23 pathway signaling and is an investigational agent that is being studied for the treatment of moderate to severe plaque psoriasis (PsO) in adult and pediatric patients.1 
  • The administration and fasting requirements of icotrokinra are described in the protocols for the ICONIC-LEAD, ICONIC-TOTAL, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 clinical trials.1-4   

protocol Information

ICONIC-LEAD, ICONIC-TOTAL, ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 are phase 3, multicenter, randomized controlled trials that evaluated the safety and efficacy of icotrokinra in patients with moderate to severe plaque PsO.2-4 

Administration and Fasting Requirements

Patients were instructed to take a single 200 mg tablet (swallowed whole) with 240 mL (8oz) of water at approximately the same time every day upon waking on an empty stomach. Patients were advised not to eat food for at least 2 hours before and for at least 30 minutes after administration.2-4 For adolescents with difficulty swallowing, tablets could be suspended in a glass of water and fully taken within 15 minutes.2,4

Literature Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) was conducted on 03 December 2025.

 

  

References

Show
1 Fourie AM, Cheng X, Chang L, et al. JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans. Sci Rep. 2024;14(1):17515.  
2 Bissonnette R, Soung J, Hebert AA, et al. Protocol to: Oral icotrokinra for plaque psoriasis in adults and adolescents. NEJM. 2025;393(18):1784-1795.  
3 Stein Gold L, Armstrong AW, Bissonnette R, et al. Supplement to: Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. The Lancet. 2025;406:1363-1374.  
4 Gooderham M, Lain E, Bissonnette R, et al. Protocol to: Targeted oral peptide icotrokinra for psoriasis involving high-impact sites. NEJM Evid. 2025;4(12).